Peadar Cremin, Ph.D.
Sr. Director, DMPK
Dr. Peadar Cremin has over 20 years of experience working in DMPK and Analytical Chemistry. He most recently worked at Kodiak Sciences, Palo Alto and at Cytokinetics, Inc, South San Francisco where he led the DMPK effort which led to the discovery of Aficamten a novel Cardiac Myosin Inhibitor for the treatment of Hypertrophic Cardiac Myopathy. Prior to Cytokinetics Peadar has worked at Xenoport, Santa Clara where he provided ADME/Analytical support for prodrug studies leading to a successful commercialization of Horizant, a novel prodrug of Gabapentin, used to treat restless legs syndrome and postherpetic neuralgia. In addition Dr Cremin has worked in similar roles in Relypsa, Santa Clara and at PTRL West, Hercules where he worked as a GLP study Director. Dr Cremin received his PhD in Organic Chemistry at University College Dublin and his BS from University College Cork, Ireland. He studied Natural Product metabolite elucidation at the Institute of Pharmacognosy and Phytochemistry at the University of Lausanne in Switzerland and completed a post-doc in Bioanalytical methods for the quantitation of anti-oxidant Natural Products and their metabolites in human plasma under the direction of Prof. A. Waterhouse at UC Davis.